Trials / Completed
CompletedNCT02381730
Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild · Network
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature, that is often regarded as a sub-type of age-related macular degeneration (AMD). However, PCV response to anti-vascular agents differs from the response of typical AMD. This study aims at describing the evolution of the best corrected visual acuity (BCVA) in PCV patients, 28 weeks after they receive one injection of intravitreal aflibercept (2mg).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal aflibercept | Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD) |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2017-08-31
- Completion
- 2017-08-31
- First posted
- 2015-03-06
- Last updated
- 2017-12-08
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02381730. Inclusion in this directory is not an endorsement.